EUCTR2022-000855-35-GR进行中（未招募）1 期
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus - RECAST SLE OLE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Willing and able to understand and provide written informed consent prior to any study-related procedures and to comply with all study requirements and complete study assessments.
- •2. Must have qualified for and received IP (daxdilimab or placebo) and complete the treatment period (through Day 337) in the RECAST SLE study. Subjects who discontinued early from IP in RECAST SLE are not eligible for this study.
- •3. Women of childbearing potential must have a negative urine pregnancy test on Day 1. Women of childbearing potential are defined as those who are not surgically sterile (ie, surgical sterilization includes bilateral salpingectomy, bilateral oophorectomy, or hysterectomy) or those who are not postmenopausal (defined as 12 months with no menses without an alternative medical cause and a follicle-stimulating hormone [FSH] within the postmenopausal range as established by the central laboratory during the screening period of the RECAST SLE study, unless on postmenopausal hormone replacement therapy).If a female subject becomes postmenopausal during the study (ie, 12months with no menses without an alternative medical cause, unless on postmenopausal hormone replacement therapy), a FSH test will be performed at the central laboratory. If the FSH level is within the postmenopausal range, the female subject will not be required to use contraception after that. Women of childbearing potential who are sexually active with a nonsterilized male partner must agree to use a highly effective method of contraception from signing of the ICF and must agree to continue using such precautions through the end of the study follow-up or 3months (approximately 5 half-lives) following the last dose of IP in the case of early withdrawal from the study, and refrain from egg retrieval/egg donation during this period. After this point, a decision about contraception should be made by the subject and her regular healthcare providers. Female subjects who participate in the SLE OLE are expected to maintain the same form of contraception they used during the RECAST SLE study. Sustained abstinence is an acceptable practice; however, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Note that because mycophenolate affects the metabolism of hormonal contraceptives and may reduce their effectiveness in women receiving MMF or mycophenolic acid (MPA) who are using hormonal contraceptives for birth control, the subject must employ an additional contraceptive method (eg, barrier method).
- •4. Nonsterilized male subjects who are sexually active with a woman partner of childbearing potential must agree to use a condom with spermicide from Day 1 and until 3 months (approximately 5 half-lives) after receipt of the last dose. Because a male condom with spermicide is not a highly effective contraception method, it is strongly recommended that male subjects advise their women partners of childbearing potential to use a highly effective method of contraception throughout this period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 148
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1. Any condition or change during the RECAST SLE study that in the opinion of the Investigator or the Sponsor would interfere with evaluation and interpretation of subject safety or alter the risk-benefit associated with IP administration.
- •2. Participation in another clinical study with an IP during the RECAST SLE study period.
- •3. Planned elective surgeries that in the opinion of the Investigator or the Sponsor would interfere with evaluation and interpretation of subject safety.
- •4. Any herpes zoster, cytomegalovirus, or Epstein-Barr virus infection that was not completely resolved prior to Visit 1.
- •5. Clinically significant active infection at Visit1, in the opinion of the Investigator, including ongoing and chronic infection requiring antibiotics or antiviral medication (chronic nail infections are allowed).
- •6. Pregnant or lactating females.
- •7. Receipt of any prohibited medication during the RECAST SLE study period. Receipt of any restricted medications during the RECAST SLE study period must be discussed with the Sponsor’s Medical Monitor and agreed upon prior to enrollment into this study.
研究者
相似试验
进行中（未招募）
1 期
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus ErythematosusEUCTR2022-000855-35-PLHorizon Therapeutics Ireland DAC156
进行中（未招募）
1 期
A clinical study to investigate the safety of mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints.MedDRA version: 15.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2011-005648-93-GRMedImmune Ltd400
进行中（未招募）
1 期
A clinical study to investigate the safety of mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints.Rheumatoid arthritisEUCTR2011-005648-93-GBMedImmune Ltd397
进行中（未招募）
1 期
A clinical study to investigate the safety of mavrilimumab, an antibody being developed for the treatment of moderate to severe rheumatoid arthritis, an inflammatory condition that affects the joints.Rheumatoid arthritisEUCTR2011-005648-93-DEMedImmune Ltd400
进行中（未招募）
2 期
A study to evaluate the long-term effects on health of continuous doses of Daxdilimab ? in patients affected with Systemic Lupus Erythematosus, and already previously treated in a clinical trial with same investigational drug.CTRI/2023/01/048803Horizon Therapeutics Ireland DAC